To investigate the role of wt-p53 in prostate cancer bone metastasis, we used the CRISPR/Cas9 technology to genetically ablate the endogenous TP53 expression in C4-2B cells (Supplementary Figures S1A,B). Here, TP53 is linked to prostate carcinoma.